Story

Novo Nordisk Downgraded by Berenberg on Eli Lilly's Growing Obesity Market Dominance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Novo Nordisk Downgraded by Berenberg on Eli Lilly's Growing Obesity Market Dominance
Text size
Background

Berenberg has downgraded Novo Nordisk A/S to 'Hold' from 'Buy,' arguing that rival Eli Lilly's accelerating dominance in the lucrative obesity drug market leaves little room for further expansion in the Danish pharmaceutical giant's valuation.

Lilly's Competitive Edge Sharpens

Analysts at the firm noted that Eli Lilly's competitive advantage has "sharpened materially," limiting the potential for Novo Nordisk's valuation multiples to expand. According to Berenberg, demand for Lilly's injectable Zepbound has accelerated significantly, outpacing the growth of Novo's Wegovy, particularly after the July 1 start of the Medicare GLP-1 Bridge programme.

The note suggests that Lilly is poised to dominate the Medicare channel just as it has the commercial market. Berenberg also pointed to the imminent FDA approval of Lilly’s diabetes pill, Foundayo, which is expected to fuel a full-scale direct-to-consumer advertising campaign and further bolster its market position.

Valuation and Forecasts Adjusted

Reflecting the more competitive landscape, Berenberg trimmed its price target for Novo Nordisk's Copenhagen-listed shares to DKK 305 from DKK 325. The price target for its American Depositary Receipt (ADR) was also cut to $47 from $50.

Sample IUX Markets – In-articleAd

Berenberg stated that the "easy gains" from its previous 'Buy' thesis, which was based on high expectations for the Wegovy pill, have now fully played out. With consensus forecasts for 2026 Wegovy pill sales now aligned at around DKK 15 billion, the analysts see further upside as limited. The stock currently trades at 13.4 times 2027 earnings, which is in line with the European pharmaceutical peer average.

Scrutiny on Novo's Pipeline

The firm also expressed caution regarding Novo Nordisk's drug pipeline, particularly its combination treatment CagriSema. Berenberg highlighted "significant investor scepticism" and a potentially difficult sales ramp for the drug, citing what it described as lackluster Phase 3 data. Consequently, the bank has trimmed its sales forecasts for CagriSema.

Looking ahead, Berenberg identified potential near-term catalysts for Novo Nordisk, including expected FDA approvals in the fourth quarter and a Capital Markets Day on Sept. 21. The analysts also flagged that bolt-on acquisitions are likely as the company faces a strategic need to diversify beyond its key drug, semaglutide, ahead of its patent expiry in 2031-2032.

Read next

More on Stocks
Back to latest news

LATEST